IQVIA (IQV) is currently in Phase 18 of its 18-Phase Adhishthana Cycle. On the surface, the stock might appear poised for a new move, but when analyzed through a multi-timeframe lens using the Adhishthana Principles, the picture is more complex. IQV seems to be caught in a prolonged time spiral that may not resolve until 2030. Let's break down its structure.The Adhishthana Cycle So FarIQVIA began its Adhishthana Cycle on 6 May 2013. Up to the completion of Phase 17, the stock maintained an impressive 88.88% ...

Summary of IQVIA (IQV) 2025 Conference Call Company Overview - **Company**: IQVIA (IQV) - **Industry**: Life Sciences Tools and Diagnostics Key Financial Highlights - **Q1 Performance**: Revenue exceeded the high end of guidance, EBITDA was above the midpoint, and EPS was at the high end of guidance [3][4] - **TAS Growth**: TAS experienced over 7.6% growth at constant currency [3] - **Cash Flow**: Cash flow increased by 13% year-over-year, representing 89% of adjusted net income, which is at the high end of forecasts [4] - **Revenue Guidance**: Revenue guidance was raised by $275 million, primarily due to foreign exchange (FX) impacts [4] - **Bookings**: Book-to-bill ratio was 1.02, with a noted slowdown in decision-making and an increase in the time between RFPs and awards by about 10% [5][6] Industry Dynamics - **Emerging Biopharma vs. Large Pharma**: Emerging biopharma is experiencing a slowdown in funding, while large pharma is facing delays in decision-making due to uncertainty from recent government actions [8][9] - **Funding Environment**: The funding environment for biotech has been weak year-to-date, impacting order placements and decision-making [10][11] - **Regulatory Environment**: Concerns regarding agency changes, tariffs, and pricing actions are affecting large pharma's decision-making processes [13][14][17] Market Trends - **Real World Evidence (RWE)**: Growth in RWE is driven by the introduction of new drugs and increased scrutiny from payers for evidence of effectiveness [29][32] - **TAS Business**: The TAS segment is expected to continue its recovery, supported by new drug approvals and the need for commercialization support [22][23][26] Competitive Landscape - **Pricing Pressure**: Increased competition has led to pricing pressures, particularly in the FSP business, but management is focused on offsetting this with cost reductions [40][41] - **Market Dynamics**: Smaller CROs are feeling more pressure for business, which may lead to increased pricing competition [42] Margin and Growth Outlook - **Margin Projections**: Adjusted EBITDA margin is projected to contract by 20 basis points due to FX impacts, but long-term margin growth is expected to remain stable [45][49] - **Revenue Growth Expectations**: Anticipated constant currency revenue growth of 6-9% annually, driven by pharma spending, market share expansion, outsourcing, and M&A [49][50] Capital Deployment Strategy - **M&A and Share Repurchase**: The company is focused on M&A and share repurchase, with a preference for M&A opportunities that enhance growth capabilities [51][54] - **Debt Management**: Comfortable with current debt levels, with a net leverage ratio between 3.3 and 3.5 [52] Underappreciated Aspects - **Business Model**: IQVIA is not a pure CRO; its TAS business represents 40% of operations, which is often overlooked in comparisons with CRO peers [57][58] This summary encapsulates the key points discussed during the IQVIA conference call, highlighting the company's financial performance, industry dynamics, market trends, competitive landscape, margin outlook, capital deployment strategy, and aspects of the business that may be underappreciated.

Have you evaluated the performance of IQVIA Holdings' (IQV) international operations during the quarter that concluded in March 2025? Considering the extensive worldwide presence of this clinical testing company, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and grow ...

Core Insights - IQVIA Holdings reported $3.83 billion in revenue for Q1 2025, a year-over-year increase of 2.5% and an EPS of $2.70, up from $2.54 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $3.77 billion by 1.55%, and the EPS also surpassed the consensus estimate of $2.63 by 2.66% [1] Financial Performance Metrics - The backlog stood at $31.5 billion, slightly above the average estimate of $31.43 billion from two analysts [4] - Revenue from Technology & Analytics Solutions was $1.55 billion, exceeding the estimated $1.52 billion, reflecting a 6.4% increase year-over-year [4] - Revenue from Research & Development Solutions reached $2.10 billion, slightly above the $2.08 billion estimate, with a year-over-year change of 0.3% [4] - Revenue from Contract Sales & Medical Solutions was $181 million, below the estimated $183.42 million, showing a year-over-year decline of 4.2% [4] - Segment profit for Technology & Analytics Solutions was $360 million, compared to the estimated $365.56 million [4] - Segment profit for Contract Sales & Medical Solutions was $11 million, below the estimated $15.65 million [4] - Segment profit for Research & Development Solutions was $460 million, compared to the estimated $471.69 million [4] Stock Performance - IQVIA shares have returned -0.5% over the past month, while the Zacks S&P 500 composite increased by 11.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Performance - Revenues for Q1 2025 increased by $92 million, or 2.5%, to $3,829 million compared to Q1 2024, driven by a constant currency revenue growth of approximately $129 million, or 3.5%[89] - Total revenues for the first quarter of 2025 were $3,829 million, an increase of $92 million, or 2.5%, compared to $3,737 million in the same period of 2024[99] - Income from operations for Q1 2025 was $558 million, while net income was $173 million[136] Cost and Expenses - Cost of revenues, exclusive of depreciation and amortization, rose by $87 million to $2,531 million, representing 66.1% of revenues, compared to 65.4% in Q1 2024[90] - Selling, general and administrative expenses remained consistent at $508 million, accounting for 13.3% of revenues, a slight decrease from 13.6% in Q1 2024[91] - The company reported a constant currency increase in cost of revenues of approximately $137 million, or 5.6%, for Q1 2025[90] - Restructuring costs increased to $29 million in Q1 2025 from $15 million in Q1 2024, aimed at streamlining global operations and integrating acquisitions[93] Segment Performance - Technology & Analytics Solutions contributed a $110 million increase in revenues, while Contract Sales & Medical Solutions saw a $4 million decrease[89] - Technology & Analytics Solutions segment revenues increased by $93 million, or 6.4%, to $1,546 million, driven by constant currency growth of approximately $110 million, or 7.6%[101] - Research & Development Solutions segment revenues were $2,102 million, a slight increase of $7 million, or 0.3%, with a constant currency growth of approximately $23 million, or 1.1%[108] - Contract Sales & Medical Solutions segment revenues decreased by $8 million, or 4.2%, to $181 million, primarily due to volume-related decreases in services performed[114] - The total segment profit for the first quarter of 2025 was $496 million, compared to $506 million in the same period of 2024[99] - Research & Development Solutions' contracted backlog increased from $31.1 billion to $31.5 billion, with an expected revenue conversion of approximately $7.9 billion in the next twelve months[107] Tax and Equity - The effective income tax rate for Q1 2025 was 18.9%, up from 14.4% in Q1 2024, influenced by changes in the geographical mix of earnings[96] - Equity in losses of unconsolidated affiliates increased to $13 million in Q1 2025 from $3 million in Q1 2024, reflecting operational results of unconsolidated affiliates[98] Cash Flow and Financing - Cash balance as of March 31, 2025, was $1,740 million, an increase from $1,702 million as of December 31, 2024[119] - Net cash provided by operating activities increased by $46 million to $568 million in the first quarter of 2025, driven by increases in cash from accounts receivable and unbilled services[127] - The company repurchased 2.3 million shares for $425 million under its equity repurchase program, with remaining authorization to repurchase up to $2,588 million[122] - Net cash used in financing activities increased by $152 million to $(258) million in Q1 2025 compared to $(106) million in Q1 2024, primarily due to higher cash payments on debt and stock repurchases[129] - Cash payments for debt and principal payments on finance leases totaled $2,053 million in Q1 2025[129] Indebtedness and Assets - Total indebtedness as of March 31, 2025, was $14,389 million, with $895 million of additional available borrowings under the revolving credit facility[123] - Total current assets decreased from $935 million as of December 31, 2024, to $629 million as of March 31, 2025[136] - Total current liabilities slightly increased from $3,792 million as of December 31, 2024, to $3,809 million as of March 31, 2025[136] - Total noncurrent liabilities increased from $12,333 million as of December 31, 2024, to $12,626 million as of March 31, 2025[136] - Amounts due from non-Guarantor subsidiaries decreased from $4,952 million to $3,718 million from December 31, 2024, to March 31, 2025[136] Debt Issuance - The company issued $1,250 million in 6.250% senior secured notes due 2029 and $750 million in 5.700% senior secured notes due 2028, raising a total of $2,000 million in gross proceeds[130] Currency Impact - Approximately 30% of revenues in Q1 2025 were denominated in currencies other than the US dollar, impacting financial results due to foreign currency fluctuations[87] Corporate Governance - The company reported no material changes to its critical accounting policies or market risk disclosures compared to the previous year[139][140] AI Commitment - The company is committed to using AI responsibly, with a focus on privacy, regulatory compliance, and patient safety in its service offerings[82]

IQVIA Holdings Analytics Inc. (IQV) has reported impressive first-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.Adjusted earnings were $2.70 per share, outpacing the Zacks Consensus Estimate by 2.7% and rising 6.3% on a year-over-year basis. Total revenues of $3.8 billion surpassed the consensus estimate by 1.6% and grew 2.5% from the year-ago quarter.The IQV stock has lost 33.5% over the past year compared with the 11.5% decline of the industry it belongs to and agai ...

Q1 2025 Earnings Call May 6, 2025 IQVIA Template (V2.1.0) 100% 50% 75% 25% 1 Legal This presentation should be viewed in conjunction with IQVIA's Q1 2025 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our second-quarter a ...

IQVIA Holdings (IQV) came out with quarterly earnings of $2.70 per share, beating the Zacks Consensus Estimate of $2.63 per share. This compares to earnings of $2.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.66%. A quarter ago, it was expected that this clinical testing company would post earnings of $3.10 per share when it actually produced earnings of $3.12, delivering a surprise of 0.65%.Over the last four quarters, ...

IQVIA (IQV) Q1 2025 Earnings Call May 06, 2025 09:00 AM ET Company Participants Kerri Joseph - SVP of Investment Relation & TreasuryAri Bousbib - Chairman & Chief Executive OfficerRon Bruehlman - Executive Vice President & Chief Financial OfficerShlomo Rosenbaum - Managing DirectorMichael Ryskin - Managing DirectorJailendra Singh - Managing DirectorDave Windley - Managing Director Conference Call Participants Justin Bowers - AnalystMatt Sykes - AnalystEric Coldwell - Senior Research AnalystTejas Savant - Ex ...

IQVIA (IQV) Q1 2025 Earnings Call May 06, 2025 09:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. As a reminder, this call is being recorded. I would now like to turn the call over to Cary Joseph, Senior Vice President, Investor Rel ...